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Since the ﬁrst report describing nitric oxide (NO) in the mid-1980s, research efforts have been devoted to elucidating the pathway of NO
generation and the mechanism of NO function in vivo. The worldwide expansion of NO investigations have helped advance progress in
biomedical device applications of NO-based strategies for cardiovascular devices, wound healing and antimicrobial agents, including recent
in vivo investigations. Here we describe the general concepts of NO discovery, mechanisms of NO synthesis in vivo and NO producing materials.
Both design strategies and results are discussed and compared in release kinetics, NO dose and biological effects, with the aim of providing
foundations for the development of new NO-based therapeutics.
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Prior to 1987, NO was generally regarded as a pollutant in
the environment produced from factory fumes, exhaust emis-
sions and electrical storms. The sensational discovery by
Robert Furchgott, Louis Ignarro and Ferid Murad that the
endothelium-derived relaxing factor (EDRF) was in fact NO
marked the beginning of a major worldwide expansion in NO
investigation not only in the basic sciences but also in applied
sciences [1]. Meanwhile, research efforts have been devoted to
elucidating the pathway of NO generation and the mechanism
of NO function in vivo. Thereafter NO is known as a diatomic
free radial endogenously synthesized in the body, and is
generated when L-arginine is converted to L-citrulline by
nitric oxide synthases (NOS) [2,3].
With research ongoing and knowledge increasing, NO has
been found to present manifold physiological and pathophy-
siological functions associated with cardiovascular homestasis,
immune response to infection, wound repair, tumor biology
and pathology [4–7]. It was declared as the “molecule of the
year” by the journal Science in 1992. NO-based strategies hold
promise for a number of biomedical applications including
cardiovascular regulation, antimicrobial action and wound
healing. In terms of the cardiovascular system, NO is naturally
produced by endothelial cells (ECs) to maintain a healthy
microenvironment surrounding blood vessels by supporting the
smooth ﬂow of blood to all parts of the human body. NO
inﬂuences the cellular behavior of circulating platelets and
monocytes. The activation of them could lead to further
aggregation and ultimately initiation of thrombosis, as well
as acceleration of atherosclerotic process and unexpected
immune system response [8–12]. Simultaneously, NO is
involved in tumor biology as an intricate balance where both
NO concentration and lifetime affect whether it acts as a tumor
progressor or suppressor [13]. NO-based therapeutic presents
excellent antibacterial candidates as it is at the crux of the
innate immune system of higher organisms [14]. Finally, NO-
based strategies can promote good wound healing. The
scientiﬁc community has gradually developed an understand-
ing of the many functions of NO and the underlying principle
involved [15].
In addition to NO’s numerous physiological functions, the
effects of NO are often localized due to its short half-life, rapid
diffusion and high reactivity [2]. Many studies of NO's
importance to physiology have focused on exposing biological
targets to different concentrations of NO and exploring
changes to cellular activity [16]. Taking these factors into
account, NO dose and release kinetics properties should be
considered in developing NO-based therapeutics. Generally,
current NO-based therapies can be classiﬁed into two cate-
gories: materials that directly release active NO or act as NO
redox catalysts, and drugs that regulate the enzymatic produc-
tion of NO from the body. In addition, several promising
strategies are based on altering NOS activity to regulate
endogenous NO concentrations [17–21]. Many studies have
focused on constructing NO-releasing and NO-generating
materials. NO gas loading as well as synthesis, incorporationand covalent attachment of NO donor compounds are the
major methods of NO delivery [22]. However, challenges such
as the short half-life of most NO donors and lack of targeted
NO delivery are the still restrictions in the commercialization
of NO-releasing materials. NO-generating materials mainly
mimic the capability of the selenium-contacting enzyme,
glutathione peroxidase (GPx) that exists in blood, by cataly-
tically decomposing RSNO into NO with the presence of
glutathione (GSH) as the reducing substrate [23]. The potential
advantage of NO-generating materials is that a sustained NO
ﬂow can be achieved through the constant level of endogenous
RSNO in circulating blood [24]. Endogenous RSNOs could be
decomposed to release NO in the presence of catalysts such as
thiol-containing agents like L-cysteine, organoselenium, tran-
sition metal-ions derived from Cu2þ , Hg2þ , Fe2þ , Agþ or
tellurium [12]. These catalysts are highly selective for reduc-
tion of S-nitrosothiol.
This review will cover the biomedical applications asso-
ciated with NO-based strategies for cardiovascular devices,
wound healing and antimicrobial agents, with emphasis on
recent in vivo investigations. Of these, primary attentions will
be paid to NO-based modiﬁcations of extracorporeal circuits,
vascular stents and bypass grafts of cardiovascular devices.
Both the design strategies and results are discussed and
compared in release kinetics, NO dose and biological effects,
with the aim of providing a foundation for developing new
NO-based therapeutics. General concepts behind the discovery
of the NO signaling pathway and the main types of NO donors
as well as NO-releasing and NO-generating materials are also
discussed.
2. Production of nitric oxide
As a gas and diatomic free radical with an unshared
electron, NO regulates an ever-growing list of biological
processes. NO can function as an intracellular messenger, an
autacoid, a paracrine substance, a neurotransmitter, or a
hormone that can be carried to distant sites for diverse effects
that are either cyclic guanosine monophosphate (cGMP)
dependent or independent, altering and regulating important
biochemical and physiological events in cell regulation and
function. Thus it is a unique simple molecule with an array of
signaling functions [1]. However, the discovery and identiﬁca-
tion of NO has taken a long time, with twists and turns.
2.1. Discovery of nitric oxide
Early in 1980, Furchgott and Zawadzki ﬁrst described the
phenomenon of endothelium-dependent relaxation, whereby
acetylcholine relaxes isolated preparations of blood vessels
with an intact vascular endothelium lining the vessels. Subse-
quently it was demonstrated that various arteries from different
species of animals exhibited relaxation in response to acet-
ylcholine only in the presence of ECs. Acetylcholine-induced
relaxation of transverse strips revealed that acetylcholine
stimulated the produce of a diffusible relaxing substance by
ECs, which was later referred as EDRF [25,26]. Within a few
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including calcium ionophore A23187, ATP and ADP, hista-
mine, serotonin, substance P, vasopressin and bradykinin, were
identiﬁed by organ-chamber experiments using rings or strips
of blood vessels [27]. Meanwhile, the inhibition of endothe-
lium-dependent relaxation of arteries in early experiments was
found to be attributable to anoxia and other agents, which were
regarded as inhibitors in the metabolic pathway of arachidonic
acid (AA) from phospholipids by lipoxygenase [25,28]. At that
time, a positive relationship between increase in cGMP and
relaxation in certain smooth muscles had been reported [29–
32]. Besides, guanylate cyclase (G-cyclase) was obviously
stimulated by hydroperoxides of AA [33,34]. The conjecture
that acetylcholine-induced relaxation of blood vessel would
stimulate a rise in cGMP was soon conﬁrmed. It was consistent
with the speculation that the increase in cGMP of muscle cells
plays a crucial role in relaxation [35–39]. There was an up-
regulation in cGMP expression during the endothelium-depen-
dent relaxation of rat aorta by A23187 and histamine and of
rabbit aorta by A23187 [35,37]. It is noteworthy that at this
very time, Murad and co-workers reported that NO is the
proximal activator of G-cyclase, and some agents (e.g.
nitroprusside, glyceryl trinitrate, azide) had been proposed to
increase cGMP and induce relaxation of certain non-vascular
smooth muscle [31,32]. Moreover, Ignarro and his colleagues
had proved that NO and nitroprusside induced relaxation of
bovine coronary artery also related to elevation of cGMP [40].
For the inhibition of endothelium-dependent relaxation, hemo-
globin (Hb) and methylene blue (MB) agents were widely
used. Hb was found to inhibit guanylate cyclase in cellular
extracts and the relaxation of muscle strips in response to nerve
stimulation and acid-activated tissue extract [31,41]. MB has
been shown to inhibit G-cyclase, endothelium-dependent
relaxation as well as inhibit cGMP up-regulation that produced
by ACh in bovine arteries and by A23187 and ACh in rabbit
aorta [37–39,42]. With the development of perfusion-bioassay
procedures, it has been found that EDRF plays a role in
physiological processes under the regulation of blood pressure
and control of regional blood ﬂow, as evidenced by a higher
EDRF release rate with increased shear stress [43,44].
It was subsequently reported that relaxation induced by
either nerve stimulation or bovine retractor penis (BRP)
muscle extract was both inhibited by Hb and involved in the
increase of cGMP in muscle. The similarities of the transient
relaxation induced by acid-activated BRP inhibitory factor
extract and rabbit aorta transient relaxation by acidiﬁed
solutions of sodium nitrite (NaNO2) caused concern [41,45].
With the awareness that HNO2 produced by acidiﬁcation of
NaNO2 solution generating low concentrations of NO and NO2
due to a reversible dismutation, the acid-activated BRP
inhibitory factor was considered to be inorganic nitrite by
Furchgott [27]. By the time of using acidiﬁed nitrite solution as
a source of NO during experiments, there was an existing
assumption that free radical NO may rapidly react with the
superoxide anion (O2
). With the ﬁndings that O2
 rapidly
inactivates EDRF and superoxide dismutase (SOD) protects
EDRF from inactivation, the possibility that EDRF might beNO was ﬁnally pointed out [45,46]. During a symposium in
Rochester in 1986, Furchgott presented his proposal that
EDRF might be nitric oxide, and Ignarro proposed this
hypothesis at the same conference independently [47]. At that
time, EDRF was recognized as a labile, small and lipophilic
molecule that was inactivated by oxygen and oxygen-derived
radicals, activated cytosolic G-cyclase via heme-dependent
mechanisms, induced smooth muscle relaxation and inhibited
platelet adhesion and aggregation through cGMP signal path-
way, meanwhile the actions were blocked by MB or hemo-
proteins but enhanced by oxygen radical scavengers or
antioxidants [1]. It was soon agreed that NO and EDRF
resemble one another in biological and chemistry character-
istics as evaluated by perfusion-bioassay procedures. The
similar properties include relaxation of vascular smooth muscle
accompanied by cGMP increase, decay rates, inhibitory effect
by Hb, MB and superoxide generators, and the stabilization by
SOD [48,49]. Additionally, the product of the reaction between
NO and Hb was the same as the product of EDRF and Hb also
provided evidence. These ﬁndings made complete sense and
ﬁnally led to the identiﬁcation of EDRF as NO. Thus this
Nobel Prize-winning discovery in physiology and medicine by
L.J. Ignarro, R.F. Furchgott and F. Murad inaugurated an
extensive well of investigations on the impact of NO in
physiology and pathophysiology as well as therapeutics for
certain biomedical applications.
Interestingly, the classic nitrovasodilators, organic nitrate
and nitrite esters such as nitroglycerin, amyl nitrite, isosorbide
dinitrate, isosorbide 5-mononitrate and nicorandil have been
used in the treatment of cardiovascular diseases (CVDs) for
more than a century. In fact, organic nitrates are both the oldest
and still most commonly used NO donor drugs. Nitroglycerin
or Glyceryl trinitrate (GTN) has been used for decades to treat
symptomatically angina chest pain, whereas slower release
therapeutics, such as isosorbide mononitrate, are used for the
treatment of hypertension and chronic angina [50]. The rapid
action of nitroglycerin and its established efﬁcacy make it the
mainstay of angina pectoris relief [51]. GTN contains 3 nitrate
groups and can release 1 molar equivalent of NO from the
terminal position after bioactivation [50]. It’s much earlier than
the discovery of active molecule NO.
2.2. Mechanisms of nitric oxide synthesis in vivo
NO synthesis in mammalian cells is catalyzed by the
enzyme NOS utilizing L-arginine as the substrate, with the
participation of reduced nicotinamide–adenine–dinucleotide
phosphate (NADPH) and molecular oxygen [2,3]. There are
three distinct isoforms of enzyme NOS cloned from numerous
tissues, referred to as neuronal (nNOS or NOS 1), inducible
(iNOS or NOS 2) and endothelial NOS (eNOS or NOS 3)
respectively [48,52]. Flavin mononucleotide (FMN), ﬂavin
adenine dinucleotide (FAD) and (6R-) 5,6,7,8-tetrahydro-L-
biopterin (BH4) are also involved in the NO synthesis process
as cofactors of all isozymes [53]. An active NOS transfers
electrons from NADPH to the heme located in the oxygenase
domain through the FAD and FMN at the reductase domain.
Fig. 1. (A) Endogenous synthesis of nitric oxide. (B) Important functions of
the different NOS isoforms. Adapted from a review originally published in
Ref. [53], copyright © OUP.
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cular oxygen, BH4 and the substrate L-arginine [54,55]. The
electrons at the heme site would activate O2 and oxidize
L-arginine to L-citrulline and NO. Endogenous NO is pro-
duced in two steps by NOS enzymes (Fig. 1A). Firstly, NOS
hydroxylates L-arginine to produce NW-hydroxy-L-arginine
(NHA), which contains a –C(NH2)¼NOH group and remains
mostly binding to the enzyme. And then, NOS oxidizes NHA,
which results in oxidative cleavage of the C¼N bond of NHA
and hence producing NO and L-citrulline [56]. All isoforms of
three NOS contain heme and bind with calmodulin. For nNOS
and eNOS, the calmodulin binding increases with up-regula-
tion in intracellular Ca2þ (half-maximal activity between 200
and 400 nM). It improves the electron ﬂow from the reductase
domain of NADPH to the oxygenase domain of heme whereby
calmodulin afﬁnity to the increase of NOS. However calmo-
dulin can be bound at very low intracellular concentrations
(even below 40 nM) in iNOS because of the different amino
acid structure at the calmodulin-binding site [57,58].
nNOS is constitutively presented in speciﬁc neurons of the
central and peripheral nervous system and some other cell
types (Fig. 1B). Of these, skeletal muscle is the largest source
of nNOS in tissue mass [53]. It has been involved in synaptic
plasticity associated with neurogenesis, learning and memory
formation. nNOS-formed NO is associated with central reg-
ulation of blood pressure in the central nervous system (CNS)
[59–61]. For the peripheral nervous system, nNOS-derived NO
can be regarded as an atypical neurotransmitter which inducesNO-sensitive G-cyclase in its target cells, thus relaxing
numerous types of smooth muscle including blood vessels
[62]. There is a notion that nNOS can function effectively in
the mediation of vascular tone that is independent of inﬂuences
of nNOS from CNS. It is noteworthy that there is low
expression of nNOS from vascular smooth muscle cells which
could help to maintain vasodilation to a certain degree when
the predominant eNOS is dysfunctional [63]. nNOS-containing
nitrergic nerves are of great importance for penile erection via
regulating corpus cavernosum smooth muscle relaxation based
on cGMP, which can be degraded by phosphodiesterases. At
least one minimal residual nNOS activity is required for the
pro-erectile effects of phosphodiesterase 5 inhibitors sildenaﬁl,
vardenaﬁl and tadalaﬁl [64–66]. However, hyperactive nNOS
enhanced by massive Ca2þ inﬂux into neuronal cells is related
to neuronal death in cerebrovascular stroke and disturbances of
smooth muscle tone within the gastrointestinal tract due to the
excitotoxicity and energy depletion of high NO levels [67–70].
The expression of iNOS is not usual in cells, but can be
stimulated by cytokines, lipopolysaccharide and other agents.
Despite the initial identiﬁcation in macrophages, the expres-
sion of the enzyme can be induced in almost any cell or tissue
type. Consequently, iNOS can be up-regulated in numerous
types of inﬂammatory disease as well, and the produced NO
regulates various symptoms of inﬂammation (Fig. 1B). Mean-
while the iNOS constant remains activity and is not mediated
via intracellular Ca2þ concentrations once expressed [53].
Thus the production of a large amount of NO caused by iNOS
would produce cytotoxicity to cells. NO can inhibit the activity
of essential enzymes containing iron at the catalytic centers by
its afﬁnity to protein-binding iron, thus inﬂuencing mitochon-
drial electron transport, citric acid cycle and DNA replication
[71]. Moreover, high concentration of NO also interacts with
DNA of target cells and further causes strand breaks and
fragmentation [72,73]. Therefore the combination of these
effects might be responsible for the cytostatic and cytotoxic
inﬂuences of NO on certain tumor cells and parasitic micro-
organisms. Interestingly, the amount of iNOS-derived NO is
large enough to inﬂuence neighboring cells [53]. Thus the
releasing site should be precise, otherwise the high level of NO
might be toxic to not only the undesired tumor cells, parasites
or microbes, but also to healthy cells. There is an abundance of
activated neutrophils and macrophages connected to autoim-
mune lesions and most inﬂammatory, therefore the NO
secreted by these cells can damage the surrounding tissue
[73,74]. The damage may be attributed to NO or its oxidation
product, peroxynitrite (ONOO). Additionally, the production
of iNOS is also likely to be associated with non-speciﬁc
allograft rejection and synergized with hypoxia to simulate
neuronal death as NO inhibits cytochrome oxidase leading to
excitotoxicity and glutamate release [75–77]. Lastly, iNOS-
derived excess NO is predominantly responsible for the fall in
blood pressure seen in septic shock [78,79].
eNOS is mostly expressed in ECs. The Ca2þ -activated
calmodulin is responsible for the mediation of membrane-bound
eNOS activity but is less dependent for Golgi-associated eNOS
[80]. Membrane-bound eNOS synthesizes NO in a pulsatile
Fig. 2. The L-arginine/nitric oxide and cGMP pathway [89].
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lular concentration of Ca2þ increases as Ca2þ stimulates the
bonding of calmodulin with the enzyme [58]. There are others
agents that interfere with eNOS and alter its activity, including
heat shock protein 90, caveolin-1, ﬂuid shear stress, as well as
phosphorylation sites on a few serine, threonine and tyrosine
residues [81–84]. eNOS seems to be capable of homeostatically
regulating various critical cardiovascular functions and is also
essential to adaptive vascular remodeling to chronic changes in
ﬂow [85]. Endothelial NOS-derived NO relaxes blood vessels of
all types via stimulating soluble guanylyl cyclase (sGC) and up-
regulating cGMP of smooth muscle cells (shown in Fig. 2) [86–
89]. NO released towards vascular lumen can inhibit platelet
aggregation and adhesion to the vascular wall, thus preventing
the secretion of platelet-derived growth factors that induce
smooth muscle proliferation and production of matrix mole-
cules, and hence protecting from thrombosis [90–92]. eNOS-
derived NO also regulates the expression of genes associated
with atherogenesis. NO reduces the expression of chemoattrac-
tant protein MCP-1 and of numerous surface adhesion mole-
cules, thus preventing leukocyte from adhering on vascular
endothelium and from migrating into the vascular wall [93–95].
These physiological responses play a role in protecting ECs
against apoptosis induced by pro-inﬂammatory cytokines, pro-
atherosclerotic factors and early events of atherogenesis [96].
NO has been shown to suppress intracellular DNA synthesis,
mitogenesis, and migration and proliferation behavior of smooth
muscle cells, which is likely associated with cGMP signal
pathway [97–100]. Therefore NO can also hinder the later phase
of ﬁbrous plaque formation in atherogenesis. In addition, eNOS-
derived NO has shown other important biological functions such
as anti-atherogenic properties through reducing endothelial
permeability, decreasing inﬂux of lipoproteins into the vascular
wall and suppressing low-density lipoprotein oxidation. Taking
these combining effects into account, eNOS-derived NO can be
considered as an anti-atherosclerotic principle [101]. Moreover,
eNOS-derived NO has been reported to be signiﬁcant for
collateral formation and angiogenesis post-ischemia, and has
the ability to regulate the downstream signals of angiogenic
factors [102]. It is noteworthy that the eNOS stimulatorsimvastatin can enhance the amount of actively functional
endothelial progenitor cells in patients with myocardial infarc-
tion [103]. All in all, eNOS-derived NO is a physiological
vasodilator (Fig. 1B), and at the same time can convey
vasoprotection in several pathways.
2.3. Mechanisms of Nitric Oxide Producing Materials
The NO level induced by iNOS is responsible for the effects
and dose-dependent properties, as already shown in vitro
[104,105]. High concentrations (41 μM) of NO can cause
cell death through necrosis, and low levels (10 nM to 1 μM) of
NO are involved in anti-apoptotic effects [106]. The amount of
gaseous NO produced from healthy endothelium is at the
picomolar and nanomolar level and has been estimated to be in
the range 0.5–4 1010 mol cm2 min1 in different situa-
tions [107]. NO has a short half-life of only a few seconds (for
instance, 0.5–5 s) in vivo and its extent diffusion distance is on
the order of 0–200 μm from NO-producing cells with a high
value of diffusion constant [108]. Taking these factors into
account, NO dose and release kinetics properties should be
considered in developing NO-based therapeutics.
As a gas, NO is extremely difﬁcult to handle owing to
problems associated with a requirement for complete exclusion
of oxygen in order to limit oxidation of NO to the toxic
nitrogen dioxide molecule. Despite these obstacles, the US
Food and Drug Administration has approved the use of inhaled
NO for the treatment of hypoxic respiratory failure and
persistent pulmonary hypertension in term and near-term
infants. This approval delivery modality for NO is expensive.
The cost of the NO is $6/l, bringing the cost of treating a
newborn with this gas to almost $12,000, with a minimum
charge of $3000 to open the tank of gas for any application
[50,109]. After inhalation, NO diffuses across the alveolarca-
pillary membrane into the subjacent smooth muscle of
pulmonary vessels to active sGC and increase intracellular
concentrations of cGMP, thus relaxing smooth muscle via
several mechanisms. In addition to its pulmonary vasodilating
effects, inhaled NO has several other effects in the lung,
including causing bronchodilation and possessing anti-inﬂam-
matory and anti-proliferative effects [110]. The Neonatal
Inhaled Nitric Oxide Study Group has reported that inhaled
NO could reduce the use of extracorporeal membrane oxyge-
nation in critically ill neonates born at or near term with
hypoxic respiratory failure who had received maximal con-
ventional therapy. The results showed that NO therapy was
safe, well tolerated and relatively easy to administer [111].
Due to the inconvenience and instability of handling aqueous
solutions of native NO, there is growing interest in applying
compounds that have the ability to produce NO in situ [56].
These compounds are known as NO donors. Of these, nitrogly-
cerin might be the most prominent one, which can release one
molar equivalent of NO by trinitrate species conversion upon
inhalation, oral or transdermal administration targeting mito-
chondrial enzymes as described in Section 2.1 [50,112]. It is one
of the low molecular weight (LMW) organic nitrate donors
commonly used as vasodilator drugs in modern medicine for
Schema 1. (A) N-Diazeniumdiolate formation and decomposition of repre-
sentative secondary amine-bearing compounds, illustrating the difference
between metal cation and protonated amine formation and stabilization. (B)
S-Nitrosothiol formation and decomposition. (C) Proposed RSNO decomposi-
tion reactions by organoselenium catalyst using glutathione as reducing agent;
each species represents: diselenide (RSe-SeR), thiol (R'SH and GSH (glu-
tathione)), selensulﬁde (RSe-SR' and RSe-SG (a glutathione adduct)), seleno-
late (RSe, a conjugate base of selenol), and S-nitrosothiol (R’SNO) [23].
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pain and hypertension in CVD treatment [50,112]. However,
lack of speciﬁcity and decreased tolerance levels after prolonged
use limit their applications as NO donors. To improve the
controlled NO delivery, much attentions has been paid to
synthesizing NO donors [113]. There are many kinds of NO
donors, including organic nitrates, nitrites, nitrosamines, metal-
NO complexes, N-diazeniumdiolates (NONOates) and S-nitro-
sothilos (RSNOs) [22]. NONOates and RSNOs are two leading
candidates that represent the most widely applied NO donor
system in combination with biomaterials.
NONOates have been extensively investigated and are a
widely applied category of NO donors, which are typical
synthesized through the reaction between secondary amines,
the nucleophile adduct, and NO gas at high pressures (for
example, 5 atm) and low temperatures, usually in a solvent of
sodium methoxide or acetonitrile (Schema 1A) [114]. This
procedure brought in a diazeniumdiolate group attached to the
amine via a nitrogen atom. Thus the solid, stable compound
diazeniumdiolate species [N(O)¼NO] consist of the N¼N
(diazen) group, a positive charge (ium) and two negatively
charged oxygen atoms (diolates) [114]. The effective formation
of diazeniumdiolate demands the appearance of a second basicresidue, an added metalalkoxide base or an existing unreacted
amine substrate, thus deprotonates the amine of the backbone
and improves its nucleophilic attack to NO. The cation of
protonated additional amine or metal from an alkoxide base
stabilizes the charge of the resulting anionic NONOate [22].
They are capable of spontaneously releasing two molar equiva-
lents of biologically active NO per mole of NONOates donors
and regenerating the amine compound when exposed to physio-
logical media (37 1C at pH 7.4) by means of hydrolysis when
protonated. The release process does not need speciﬁc metabo-
lites, catalytic or redox mechanisms, which are beneﬁcial for
applying these donors in medicine, and the metabolite- and
tissue-independent release properties further enhance attraction
[115]. The predictable ﬁrst-order release kinetics of NO depend
on the exact atomic structure and amount of amine precursor,
which can vary from short time periods (seconds) to days or
even weeks due to hydrogen bonding stabilization from addi-
tional amines. Furthermore, by speciﬁc modiﬁcation in the
chemistry of NONOates, local NO release at target sites might
be achieved using a cell/tissue-speciﬁc enzyme or metabolitesas
cleavable linkers [112]. However there are concerns about
toxicity issues of nitrosamines, which are formed by hydrophilic
diazeniumdiolates leaching from the polymer matrix [116].
Different from the strictly exogenous NONOates, S-nitro-
sothilos are endogenous NO donors that exist in biologic
systems as physiological transporters of NO [117]. There are
S-nitrosoglutathione (GSNO), S-nitrosoalbumin and S-nitroso-
cysteine present in host tissues and physiological ﬂuids
including plasma and blood (7 μM) [118]. This offers
RSNOs incomparable advantages as a reservoir for NO over
NONOates, relatively reduced levels of toxicity, no build-up of
tolerance over time, transferring NOþ species without losing
active payload, decreased susceptibility to oxidation and using
circulating molecules as unrestricted localized NO supply
[119]. It has been proposed that the formation of RSNOs
occurs with NO inter- and intracellular signaling serving as an
intermediary step in vivo [120,121]. Under laboratory condi-
tions, RSNOs are formed by reactions between thiols (R-SH)
and a nitrosating agent (nitrous acid, dinitrogen trioxide or
alkyl nitrite). It is easy to conﬁrm the formation of RSNOs by
their color as they have absorbance in both the visible (550–
600 nm) and UV (225–261 and 330–350 nm) regions [113]. S-
nitroso-N-acetylpenicillamine (SNAP) and GSNO are the two
most commonly used RSNOs for in vitro investigations.
Unlike the release proﬁle of NONOates, the decomposition
of RSNOS needs additional reactions [113]. Basically, the
multiple triggers include the following ﬁve principles: (1) Ther-
mal and photolysis induced homolytic cleavage of the S-NO
bond generates a thiyl radical and NO, and the thiyl radical
product further interacts with another RSNO to generate
additional NO and a disulﬁde (Schema 1B) [122]. (2) Transi-
tion metal-mediated catalysis (e.g., copper ions) in which Cu
(II) would be reduced by trace thiolate to form Cu(I) which
then interacts with RSNOs to generate NO, the thiolate and Cu
(II). The thiolate might result in the formation of Cu(I) from
Cu(II), circulating the catalytic reactions of RSNOs to NO
(Schema 1B) [122]. (3) Transnitrosation or transfer nitroso to a
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RSH. Thus the newly produced R’SNO would be decomposed
by one of the described triggers to release NO (Schema 1 B)
[122]. (4) Direct reaction with ascorbate (the anionic form of
L-ascorbic acid) [123]. (5) Enzymatic release, such as via
protein disulﬁde isomerase or superoxide dismutasa [123].
The descriptions above can be summarized as NO-releasing
concepts, mainly focusing on encapsulation of NO and LMW
NO donors, surface grafting donors and high pressure NO to
secondary amine-functionalized agents. They are also asso-
ciated with targeting NO active species to certain proteins,
polymers, coating or metallic nanoparticles, zeolites and
molecular organic frameworks, silica particles, and doping
NO-releasing macromolecular scaffolds within the polymer
[22]. To a certain degree, NO-releasing strategies have
hindered the clinical utility of low molecular weight NO donor
compounds and NO gas due to the limited NO payloads with
untargeted and rapid NO release [22]. In the case of NON-
Oates materials, the formation and leaching of toxic nitrosa-
mines remain challenges. Further development to avoid
leaching might focus on preparing lipophilic NONOates or
using covalent immobilization method to improve the stability
of NONOates [124,125]. The biomedical application of NO-
releasing materials is limited to short-term contacting devices
or nanoparticle delivery systems.
Another design concept for introducing NO into biomedical
materials is NO-generation, mainly based on the catalytic
reaction of RSNOs decomposing to generate NO. Due to the
constant endogenous RSNO level in the body, the NO ﬂow
produced by NO-generating materials can be sustained con-
tinuously [24]. Catalytic agents include thiol-containing agents
such as L-cysteine, transition metal-ions derived from Cu2þ ,
Hg2þ , Fe2þ , Agþ , organoselenium and tellurium. The cata-
lytic mechanism of thiol-containing agents and Cu2þ is the
same as the decomposition process of RSNOs described
above. Additionally, organoselenium mimics the naturally
existing selenium-contacting enzyme GPx via catalytically
decomposing RSNO to NO with the corresponding free thiol
[23]. It has been demonstrated that enhanced S-nitrosoprotein
formation within EC occurs in the presence of small organo-
selenium molecules and GSH along with GSNO as the NO
donor [126]. Four reactions have been proposed to be involved
in the RSNO decomposition by organoselenium catalyst with
GSH as the reducing agent (Schema 1C) [127]. The presence
of GSH shifts the equilibrium in rxns 1–2 to produce
selenolate (RSe). Such selenol/selenolate species have
already been considered as active species for the reduction
of peroxides and peroxynitrite during anti-oxidant activity of
synthetic organoselenium molecules as well as GPx [127]. As
suggested by rxn 3, taking the selenolate anion as the primary
catalytic species involved in RSNO decomposition is reason-
able with a thiol and diselenide produced to complete the
catalytic cycle. Thus rxns 1–3 mainly attribute to sustained NO
evolution in the presence of a reducing agent. In addition,
direct reaction between diselenide and RSNO exists in a
stoichiometric manner (rxn 4). It can be seen that the catalytic
reactions produce a cycle and ﬁnally reach a dynamic balancestate, resulting in a constant and stable release rate of NO. This
unique property brings NO-generating materials to applications
such as orthopedic implants and cardiovascular stents, which
require long-term implant periods.
3. Nitric oxide in cardiovascular applications
CVDs, particularly atherosclerosis, remain a major cause of
morbidity and mortality throughout the world, claiming over
17 million lives annually [128]. Surgical intervention treat-
ments of narrowed arteries as a result of atherosclerosis include
traditional bypass graft surgery, vascular stents, angioplasty
and heart valve replacement [129–131]. Despite developments
in surgical techniques and enhanced pharmaceutical regimens,
there are still unavoidable complications associated with
thrombosis and restenosis in long-term outcomes [132,133].
These complications are mainly attributed to the absence or
disfunction of healthy endothelium and provoked injury-
induced inﬂammation at the implantation site [134,135]. The
absence of healthy endothelium further aggravates thrombosis
and neointimal hyperplasia (NIH), which limits clinical appli-
cations and is the principal mode of device failure [136,137].
Additionally thrombosis is a critical risk factor even in the
short term applications as blood is exposed to materials such as
catheters, intravascular sensors, hemodialysis membranes and
devices for extracorporeal circulation (ECC) [123].
The natural vascular system is protected by a non-thrombo-
genic barrier which consists of ECs attached on basement
membrane. In vivo, the endothelial lining of blood vessels
provides a thrombo-resistive surface by secreting molecules
such as the anticoagulants thrombomdulin, heparan sulfates as
well as the potent inhibitors of platelet activation prostacyclin
(PGI2), surface ADP-destroying ectoenzyme (ADPase) and the
vasodilator, NO [138–140]. NO released from vascular ECs
has been reported to be anti-thrombotic, prevent inﬂammation
and anti-NIH as NO inhibits platelet and leukocytes adhesion
and activation, and suppresses SMC proliferation and migra-
tion [141]. The inhibition of platelets and SMC is through the
cGMP signal pathway. Hence the lack (in artiﬁcial grafts/
intravascular devices) or the loss (caused by vascular injury
during PCI/bypass) of endogenous NO is responsible for
thrombosis and NIH. This has resulted in a rapid increase of
research in mimicking endothelial NO-release as an obvious
solution for improving conditions after vascular graft implan-
tation and vessel injury. NO-based strategies for modifying
cardiovascular devices including ECCs, vascular stents and
bypass grafts are discussed below.
3.1. Extracorporeal circulation
ECCs play a crucial role in numerous medical procedures
associated with blood transport, such as transfusion, blood
oxygenation and hemodialysis. Drawbacks have emerged in
the application of polymers for ECCs due to adverse physiolo-
gical response and mechanical failure. The formation of blood
clots on the surface of ECCs is an as-yet unsolved most serious
complication. The habitual use of systemic anticoagulants can
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the ECC device, including bleeding out and platelet consump-
tion. A report from the Extracorporeal Life Support Organization
of 2012 describes some alarming statistics regarding the use of
ECC devices [142]. Of the patients (16 yrsþ ) who received
ECC treatment, 7.4% of them were reported to experience
mechanical failure because of clotting in the device, and those
who experienced clotting had only a 33% chance of surviving to
discharge or transfer. Thus ECC materials with superior bio-
compatibility that can control the initial bio-response and retain
ECC functionality are in urgent need.
Polyvinyl chloride (PVC) and polyurethane (PU) are com-
monly used ECC materials. Various strategies have been
designed to improve the blood-compatibility of these poly-
meric materials. Scientists have realized that mimicking the
nonthrombogenic properties of the EC layer that lines the inner
wall of healthy blood vessels might be a promising strategy.
NO released from ECs serves as an anti-platelet agent to
control coagulation and adsorption of blood-clotting proteins
to material surfaces. Additionally, NO can prevent inﬂamma-
tion and infection, which is crucial to the performance of
ECCs. Thus intensive research has focused on designing novel
ECCs capable of NO release.
Annich et al. proposed an NO-releasing ECC circuit aimed
to prevent thrombogenesis in a rabbit model in 2000 [116].
The circuit was coated with NO-releasing polymer on the inner
surface. NO release was linear and reached a peak of about 20–
25 μmol at the ﬁrst day. However no more NO release was
detected after 24 h, thus limiting the long-term application of
this approach. Platelet consumption and activation were then
evaluated using a rabbit model of venovenous ECC in the
absence of systemic heparinization. The results showed that
NO-releasing circuits greatly suppress platelet adhesion and
activation and did not exhibit apparent thrombus formation
compared to controls. Annich and co-workers prepared another
polymer coating called Norel-b that contains DBHD/N2O2,
PVC/DOS and KTpClPB, to explore the critical ﬂux necessary
to protect platelet count and function and to inhibit platelet
activation [143,144]. Norel-b coating with a top coating of
PVC/DOS was used as an ECC circuit of a rabbit arteriove-
nous shunt model. Compared to bradykinin-stimulated
endothelial NO ﬂux (1.6–4.0 1010 mol cm2 min1) and
basal endothelial NO ﬂux (0.5 1010 mol cm2 min1)
[145], the Norel-b coating had NO ﬂuxes of 2.3, 13.7, 20.6 and
39.1 1010 mol cm2 min1 of 2, 10, 25, and 50 wt% of
DBHD/N2O2, respectively [144]. All Norel-b coatings except
2 wt% were able to maintain activated clotting time within the
baseline and protect the platelet count over the course of 4 h.
SEM images showed a signiﬁcant amount of platelet adhesion
and activation for the control groups while few platelets
adhered to Norel-b coatings. Platelet function was preserved
for all Norel-b coatings compared to the control groups, as
measured by collagen-induced aggregometry. Based on these
data, the critical ﬂux was estimated to be greater than 13.7
1010 mol cm2 min1. Annich and co-workers further cor-
related the inactivation of platelets and monocytes in Norel-b
coatings with the attenuation in the expression of P-selectin, asurface glycoprotein indicative of platelet activation, and
CD11b, a monocyte surface integrin [143]. Thrombus area
after 4 h of blood exposure was signiﬁcantly reduced in Norel-
b coatings (2.8 pixels cm2) compared to controls
(6.7 pixels cm2). Unfortunately, the leaching of NO donors
from the polymer coatings into the blood circulation might
cause the production of toxic nitrosamines [116,146,147]. To
solve the toxicity problem associated with nitrosamines,
lipophilic NONOates and covalently bound methods are in
trial.
In a covalently binding donors study, NO releasing silicone
rubber (SR) was prepared by covalently linking diamine/
triamine groups to the cured SR structure [148]. The resulting
SR ﬁlms/coatings release NO at ambient or physiological
temperature for up to 20 d with average ﬂuxes of at least
4 1010 mol cm2 min1 over the ﬁrst 4 h, comparable to
the NO ﬂuxes observed from stimulated human ECs. The NO
releasing SR materials exhibited improved thromboresistance
in vivo with no clotting, while the tubing with untreated
coating clotted within 3 h. There was also reduced platelet
activation on the surface of these polymers when coated on the
inner wall of SR tubing employed for ECC a rabbit model.
Lipophilic NONOates were chosen to prevent toxic nitrosa-
mines formation. Lipophilic dialkyldiamine-based NONOates
were prepared via reaction of the corresponding diamine with
NO [149]. More stable initial NO release can be achieved by
adding lipophilic anionic species (e.g., tetraphenylborate
derivative) to the polymeric material to buffer the activity of
protons within the organic phase. It has been shown that the
use of these new lipophilic NO-donors in polymers provides
the ability to tailor NO release rates for diverse medical
applications. As an example, polymers doped with diazenium-
diolate and tetraphenylborate derivative are employed as
coatings for vascular grafts in sheep [149]. The NO-releasing
grafts exhibit improved performance and have an average 95%
thrombus-free surface area compared to 42% for the corre-
sponding control grafts when examined after 21 days of
implantation.
For synthesizing stable PUs capable of generating bioactive
NO, two novel strategies have been described [150]. The
methods rely on covalently attaching diazeniumdiolate groups
onto secondary amine nitrogen at various positions within the
polymer chain. Fluxes of molecular NO from such materials
during immersion in physiological buffer reach levels as high
as 11.4 1010 mol cm2 min1 with a total recovery of
21 nmol of NO/mg of PU. A second general synthetic strategy
involves ω-haloalkylating the urethane nitrogens and then
displacing the halide from the resulting polymer with a
nucleophilic polyamine to form a PU with pendent amino
groups suitable for diazeniumdiolation. This material showed
an initial NO ﬂux of 8.4 1010 mol cm2 min1 when
immersed in pH 7.4 buffer at 37 1C, gradually decreasing
but still observable for up to 6 days.
As metal ions can also decompose RSNO to NO, some research
has focused on the incorporation of certain kind of elements into
polymeric materials to generate NO from endogenous RSNO in
blood. Meyerhoff and co-workers prepared polymers containing
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philic PU and polymethacrylate polymers with covalently linked
CuII-cyclen complexes have been shown to generate NO sponta-
neously from fresh sheep blood. A steady-state NO ﬂux equal to
physiological endothelium-derived NO ﬂux (i.e.,  1010
mol cm2 min1) was obtained when the polymer was immersed
in saline solution containing GSNO/GSH or CysSNO/CySH.
These authors also prepared polymeric substrates (e.g., PU
catheters and SR tubings) that are capable of decomposing RSNO
in the presence of reducing agents [152]. The surfaces were
constructed by incorporating organoselenium-modiﬁed polyethyle-
neimine and sodium alginate via a layer-by-layer technique and
then tested by sheep whole blood. In a more recent study, Puiu and
coworkers modiﬁed medical polyurethane (Pellethane and Teco-
philic) with CuII-cyclen moieties by a facile three-step synthetic
procedure [153]. The prepared materials released NO at levels that
exceeded those of ECs [154].
There is only one NO anti-coagulation agent involved in the
studies described above. To further construct excellent blood-
compatible surfaces, Zhou and Meyerhoff prepared a dual
acting polymeric coating that combined NO release with
surface-bound active heparin [155]. A trilayer membrane
conﬁguration was constructed, ﬁrst coating the substrate with
a dense polymer layer followed by a plasticized PVC or PU
layer doped with a lipophilic NONOates as the NO donor
species, and ﬁnally an outer layer of aminated polymer.
Heparin was covalently bonded to the outer layer via amide
bonds. The surface-bound heparin has been reported to possess
anti-coagulant activity by anti-Factor Xa assay. The surface
NO ﬂux from the underlying polymer layer containing the
diazeniumdiolate species can be controlled and maintained at
various levels (from 0.5 to 60 1010 mol cm2 min1) for
at least 24 h and up to 1 week (depending on the desired ﬂux
level) by changing the chemical/polymer composition of the
NO release layer. The polymeric coatings functioned by two
complementary anti-thrombotic mechanisms, one based on the
potent anti-platelet activity of NO, and the other on the ability
of immobilized heparin to inhibit Factor Xa and thrombin
(Factor IIa). Thus the polymeric coatings exhibited remarkable
enhancement in thromboresistivity compared to polymers that
utilize either NO release or immobilized heparin alone. In a
further study, multi-functional bilayer polymeric coatings were
prepared with both controlled NO release and surface-bound
active thrombomodulin (TM) alone or in combination with
immobilized heparin [156]. The outer-layer was made of
CarboSil, a commercially available copolymer of SR and
PU. The CarboSil was either carboxylated or aminated to
immobilize TM through the formation of an amide bond
between the surface carboxylic acid groups and the lysine
residues of TM or couple heparin to the surface, and then the
carboxylic acid groups on heparin can be further used to
anchor TM. Both surface-bound TM and heparin activity were
evaluated by chromogenic assay and found to be at clinically
signiﬁcant levels. The underlying NO release layer was made
with another commercial SR-PU copolymer (PurSil) mixed
with a lipophilic NO donor. The NO release rate can be
regulated by changing the thickness of the top coatings, andthe duration of NO release at physiologically relevant levels
can be prolonged to 2 weeks. The combination of controlled
NO release as well as immobilized active TM and heparin on
the same polymeric surface mimics the highly thrombo-
resistant endothelium layer.
3.2. Vascular stents
Vascular stents are utilized as a common intervention
treatment of CVDs with minimal invasive damage. Despite
all the immediate beneﬁts, the stent implantation procedure
causes unavoidable injury to the endothelium layer lining the
vessel, provoking a series of responses including inﬂammation,
proliferation and migration of SMCs, NIH and subsequent in-
stent restenosis [133,157]. Thus an ideal stent should possess
excellent hemocompatibility, anti-proliferation of SMC, and
accelerated regeneration of healthy endothelium. It is note-
worthy that NO has been shown to function in the prevention
of thrombosis, SMC proliferation and migration as well as of
leukocyte activation. In addition, NO is also associated with
atherosclerotic lesions healing and regulation of EPCs differ-
entiation and function [158]. Thus NO could be an ideal
candidate for improving current stent conditions and should be
taken into consideration in fabricating better multifunctional
stent coatings.
Localized delivery of NO has already been used in the stent
ﬁeld. For example, Seabra et al. utilized polynitrosated
polyesters (PNPEs) blended with polymethyl methacrylate
(PMMA) coated on 316L stainless steel stents [159]. RSNOs
were covalently linked to the polymer by esteriﬁcation of PEG
with mercaptosuccinic acid followed by nitrosation of –SH
moieties. The NO release rate remains constant at 1.8 and
180 nmol g1 h1 overnight, showing inhibition of platelet
adhesion. To further evaluate the effect of controlled stent-
based release of an NO donor on in-stent restenosis in rabbits,
Young et al. prepared NO-releasing PLGA microspheres
modiﬁed with PEG [160]. The NO-containing microspheres
released NO with an initial bolus in the ﬁrst week, followed by
sustained release for 3 weeks. Signiﬁcant increase in cGMP
levels and decrease in proliferating cell nuclear antigen-
positive cells were found at 7 days for the NO-treated group
relative to controls. Intima-to-media (I/M) ratio in the NO-
treated group was reduced by 46% and 32% relative to
controls at 7 and 28 days, respectively. Hence stent-based
strategies with controlled release of NO donor signiﬁcantly
reduce in-stent restenosis, which is associated with up-regula-
tion of vascular cGMP and suppression of SMC proliferation.
Guillermo A. Ameer and coworkers have recently produced
NO-releasing polydiol-co-citrate elastomers that encapsulate
aliphatic diols, citric acid and (diamine diol) as a diazenium-
diolate precursor [161,162]. The NO release kinetics can be
regulated by altering the length of aliphatic diol (e.g., 1,8-
octanediol or 1,12-dodecanediol). Poly-1,8-octanediol-co-
citrate with diamine diol (5 mol%) (POCDA10-NO) showed
a burst release under two days, while the release of poly-1,12-
dodecanediol-co-citrate containing diamine diol (5 mol%)
(PDDCDA10-NO) could be up to 21 days. The total NO
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106 mol cm2 and 6.6 109 mol cm2 min1, the values
for POCDA10-NO were 10.5 106 mol cm2 and 35.4
109 mol cm2 min1, respectively. Both polymers enhanced
EC and VSMC adhesion and proliferation in vitro. However
the cellular viability reduced with increasing NO dose. Films
of PDDCDA10-NO with a more extended NO release were
used in rat carotid arteries after balloon-induced injury, which
decreased intimal area and I/M ratio by 45% and 38%
compared to injury alone at 14 days.
The combination of a NO donor and a paclitaxel-NO donor
conjugate coated on vascular stents was tested in a rabbit iliac
artery model of stenosis as a potential therapy for restenosis
[163]. Paclitaxel was conjugated with a NO donor at the
7-position to give compound 7. An adamantane-based NO
donor 14 was synthesized and combined with 7 to provide a
burst of NO in the ﬁrst few critical hours following injury to
the vessel wall. Both 7 and 14 showed good anti-proliferative
activity (half maximal inhibitory concentration IC50¼ 20 nM
and 15 μM, respectively) and antiplatelet activity (IC50¼ 10
and 1 μM, respectively). Stents were coated with a layer of a
polymer containing test compounds. The total amount of NO
eluted after 6 h implantation in the rabbit iliac artery was 35%,
95% and 69% of the original content for the stents coated with
7, 14, and the combination of 7 and 14, respectively. Polymer-
coated stents caused inﬂammation and increased stenosis by
39% when compared to the uncoated stents. The stents coated
with 7 plus 14 were 41% better than the polymer-coated stents
and 34% better than the paclitaxel-coated stents. These resultsFig. 3. Migration of (A) HUVECs, and (B) HUASMCs on 316L SS and SeDPA-PPA
coated stents on ISR assessedby histomorphometric analysis. Percent neointimal sten
(E). Data presented as mean7SD and analyzed using one–way ANOVA, ***po0
copyright © Elsevier.reveal the beneﬁcial effect of adding NO to an anti-prolif-
erative agent (paclitaxel) and suggest a potential therapeutic
combination for the treatment of stenotic vessel disease.
Our group has long focused on constructing NO-generating
coatings for cardiovascular stents. Yajun Weng et al. have
immobilized cystamine and selenocystamine (Se) on TiO2 sur-
face for catalytic generation of NO [164,165]. In vitro platelet
adhesion results reveal that cystamine and Se modiﬁed surfaces
can inhibit collagen-induced platelet activation through the
NO/cGMP signal channel [164]. Moreover, in vivo studies have
demonstrated that Se modiﬁed stents in femoral artery model
after two months reduce the incidence of NIH, showing great
promise for cardiovascular therapy [165]. Recently Zhilu Yang
et al. have reported a NO-catalytic bioactive coating obtained by
covalent conjugation of 3,3-diselenodipropionic acid (SeDPA) to
generate NO from RSNOs (Fig. 3) [158]. The NO release rate
was 5.9770.24 1010 mol cm2 min1, and showed the
long-term and continuous ability to catalytically decompose
endogenous RSNO to generate NO. They also found that the
NO catalytic surface presents accelerated HUVECs migration
(Fig. 3A) and decreased HUASMCs migration (Fig. 3B). In vivo
results also reveal a remarkably reduced percentage of neointimal
stenosis (34.571.4% vs 20.474.1%) (Fig. 3D) and mean
neointimal area (1.7170.43 mm2 vs 0.9970.17 mm2)
(Fig. 3E) of SeDPA-PPAam coated stents compared with
316L SS stent. These NO-generating coatings showed signiﬁcant
inhibition in NIH at each NO generating rate. Thus the inhibitory
effects of different NO generating rates prepared from oneam surfaces after 1 day. (C) Effect of the control 316L SS and SeDPA-PPAam
osis (D) and mean neointimal area analysis indicated signiﬁcantly reduced ISR
.001. Adapted and reproduced from research originally published in Ref. [158],
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platforms in diverse applications.
NO-producing materials applied to vascular stents have been
reported to inhibit platelet adhesion and activation and SMC
proliferation and migration, and to reduce NIH incidence and I/M
ratio. There are still many others functions induced by NO in
vascular systems that are not discussed here, including EPC
homing and differentiation, leukocyte activation, ball-induced
injury and atherosclerosis healing. For vascular stents, the actual
operating environment is an atherosclerotic plaque microenviron-
ment. Atherosclerosis is a chronic inﬂammation in arteries,
characterized by a large amount of lipid deposition onto blood
vessel walls, a variety of inﬂammatory cells (such as macrophages,
lymphocytes and neutrophils) inﬁltration and SMCs hyperplasia.
Anti-inﬂammatory and atherosclerosis healing of NO-producing
coatings should be taken into consideration. Furthermore, in vivo
evaluation of the pathological model is necessary. The combination
of NO and other molecules should also be focused.Fig. 4. (A) Schematic diagram demonstrating site of histologic sections of arteriov
(abundance of thrombus at luminal surface of uncoated graft) and nitric oxide-releas
free of attached thrombus) (magniﬁcation 40 ). Representative photographs of
display luminal thrombus. (D) Uncoated control graft. (E) Sham-coated graft wi
releasing polymer coating on luminal surface. Explanted grafts were examined with
(G) arterial anastomoses of nitric oxide-releasing grafts, and (H) sham-coated gra
published in Ref. [167], copyright © Elsevier. Digital images of coated PVC rods a
solutions containing (I) 20 wt% KTpClPB without any NO precursor 5, and (J) 2
research originally published in Ref. [168], copyright © ACS.3.3. Bypass grafts
Polymeric materials including Dacron (polyethylene ter-
ephthalate, PET), expanded polytetraﬂuoroethylene (ePTFE)
and microporous PU have been successfully used for replacing
large-diameter (inner diameter 46 mm) blood vessels. How-
ever, they are not ideal substitutes. Thrombus formation and
eventual intimal hyperplasia are the leading causes of small-
diameter (inner diameter o6 mm) synthetic vascular graft
failure. To address these issues, Jennifer West and coworkers
have incorporated a diazeniumdiolate-modiﬁed NO-producing
peptide into polyurethane to improve the thromboresistance of
this biocompatible polymer [166]. The mechanical properties of
the material were suitable for vascular graft applications, and NO
production by polyurethane ﬁlms continued for approximately
2 months under physiological conditions. Platelet adhesion to
NO-releasing polyurethane was dramatically decreased com-
pared to control polyurethane. EC growth was stimulated in
the presence of the NO-releasing polyurethane, while SMC wasenous graft specimens. HE-stained histologic sections from uncoated graft (B)
ing graft (C) (Luminal surface has thin ﬁbrin coating in some specimens, but is
explanted polyurethane vascular grafts. Grafts were opened longitudinally to
thout nitric oxide-releasing biopolymer. (F) Graft incorporating nitric oxide-
SEM to show platelet adhesion and thrombus accumulation on graft surfaces,
fts (magniﬁcation 1000 ). Adapted and reproduced from research originally
fter implantation for 8 h prepared by dip-coating in Tecoﬂex EG-80A cocktail
0 wt% KTpClPB with 5 wt% NO precursor 5. Adapted and reproduced from
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platelet adhesion and SMC proliferation and encourage endothe-
lialization suggests that NO-generating polyurethane may be a
suitable candidate material for small-diameter vascular grafts.
NO-releasing biopolymers have the potential to prolong
vascular graft and stent potency without adverse systemic
vasodilation. 5-mm polyurethane vascular grafts coated with a
polymer containing the NO-donor dialkylhexanediamine dia-
zeniumdiolate were implanted for 21 days in a sheep arter-
iovenous bridge-graft model by Paul Fleser (Fig. 4A–H) [167].
Eighty percent (4/5) of grafts coated with the NO-releasing
polymer remained potent through the 21 day implantation
period compared to ﬁfty percent (2/4) of sham-coated grafts
and zero (0/3) uncoated grafts. The thrombus-free surface area
of explanted grafts was signiﬁcantly increased in NO-donor
coated grafts (98.2%70.9%) compared with sham-coated
(79.2%78.6%) and uncoated (47.2%75.4%) grafts. Exam-
ination of the graft surface showed no thrombus or platelet
adhesion and no inﬂammatory cell inﬁltration, while complex
surface thrombus consisting of red blood cells in an amorphous
ﬁbrin matrix was formed on the control graft surface, as well
as signiﬁcant red blood cell and inﬂammatory cell inﬁltration
into the graft wall. Thus local NO release from the luminal
surfaces of prosthetic vascular grafts can reduce thrombus
formation and prolong potency in a model of prosthetic
arteriovenous bridge grafts in adult sheep. These ﬁndings
may attribute to improving function and improving primary
potency rates in small-diameter prosthetic vascular grafts.
There remains a signiﬁcant challenge in the development of
NO-releasing materials. High temperatures during polymer
fabrication may inﬂuence NO donor stability. To address this
issue, Xu et al. developed a different lipophilic NO donor
precursor, HNBOA/N2O2, that incorporated 2-hydroxy-5-nitro-
benzyl as a diazeniumdiolate protecting group for thermal
stability [168]. At the same time, it could efﬁciently release
NO in pH 7.4 aqueous solution. A lipophilic analogue incorpo-
rated into hydrophobic polymers shows NO surface ﬂux rates
comparable to that of the natural endothelium. Importantly, these
polymer formulations also show signiﬁcantly enhanced biocom-
patibility in vivo with use of a porcine implant model (Fig. 4I–J).
There has been substantial effort directed to fabricating
materials that mimic endothelial properties. Kushwaha et al.
have recently developed a native endothelial ECM mimicking
self-assembled nanoﬁbrous matrix with the ability to release NO
to serve as a treatment model for stents and grafts [169]. The
nanoﬁbrous matrix is formed by self-assembly of peptide
amphiphiles (PAs), which contain NO donating residues, EC
adhesive ligands composed of YIGSR peptide sequence, and
enzyme-mediated degradable sites as well. NO was released
from the nanoﬁbrous matrix rapidly within 48 h, followed by
sustained release over a period of 30 days. Cumulative NO
release value of 0.32 μmol from coated metal stents was
estimated for a one-month release. The NO releasing nanoﬁbrous
matrix demonstrated signiﬁcantly enhanced proliferation of ECs
but reduced proliferation of SMCs. There was also a signiﬁcant
decrease in platelet attachment on the NO releasing nanoﬁbrous
matrix compared to the collagen-I coated surface. There was asimilar design in which ePCL nanoﬁbers were coated with cell-
adhesive ligands and NO-releasing PAs by a solvent evaporation
technique [170]. The presence of YIGSR ligands and release of
NO promoted the adhesion and proliferation of ECs while
simultaneously limiting the adhesion and proliferation of SMCs
and the adhesion and activation of platelets. NO was released
over 28 days, with an initial burst release occurring in the ﬁrst
48 h followed by slow sustained release over a period of 4 weeks,
resulting in 48% recovery of NO. It has been reported that a total
NO release of 3.8 μmol over 4 weeks is comparable to the
cumulative NO amount released from ECs at the rate of
1010 mol cm2 min1 [171]. Taite et al. encapsulated YIGSR
ligands into PU-PEG copolymer with lysine-containing peptides
acting as diazeniumdiolate NO donors whose NO was released
as an initial burst (70%) followed by a sustained release for over
2 months [172]. These materials were found to enhance EC
adhesion and proliferation, as well as inhibit platelet adhesion
and SMC adhesion and proliferation.
Lewis et al. reported that modiﬁed PET and PU with thiol
groups can promote the transfer of NO from RSNOs naturally
found in plasma and whole blood solutions [173,174]. L-cysteine
was covalently immobilized onto PU and pPET. The number of
platelet adhered on the L-cysteine-modiﬁed polymers was
reduced by more than 50% as compared to the control
(glycine-modiﬁed polymers) when the platelet suspension con-
tained plasma constituents. These results suggest that L-cysteine-
modiﬁed polymers are effective in reducing platelet adhesion via
the transfer of NO from endogenous S-nitrosoproteins in plasma
to the polymer followed by the subsequent release of NO [173].
Furthermore, the immobilized concentration of thiol groups from
each of the optimized processes increased in order with the
following groups: cysteine polypeptideo2-iminothiolane
oL-cysteine. All of the polymers demonstrated a signiﬁcant
decrease in platelet adhesion compared to controls when exposed
to the BSANO, plasma and whole blood solution. The most
signiﬁcant decrease was in the L-cysteine modiﬁed polymer in
plasma solution (with a 65% decrease) [174].
NO-producing strategies for bypass grafts, which release
NO at rates similar to native endothelium, show signiﬁcant
improvement in the treatment of vascular occlusive disease and
avoid the need for prolonged anti-coagulant therapy. Addi-
tionally, NO-based strategies of constructing structure and
function mimicking vascular vessels seem to be the best
candidates for the development of biomaterials for vascular
substitutes. Excellent hemocompatibility, enhancement in EC
attachment, proliferation and migration, stimulus of SMC
proliferation and migration, differentiation of mesenchymal
stem cells are indicated. The mechanisms of how the vascular
cells attach to material surfaces and release NO, and the how
the NO functions during different phases of the body healing
process are likely to be clariﬁed in the near future.
4. Nitric oxide in wound healing
Wound healing is crucial to the recovery of body integrity
after injury, with the need to restore function and anatomical
structure back to a baseline level. It is characterized by a
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matory cell inﬁltration, coordinated by various biological
factors [175]. Wound healing process immediately begins
following injury and might last for several months. An ideal
wound repair goal might be rapid recovery with maximal
function and minimal scarring. Prior to the 1960s, passive
wound dressing to protect the wound from physical contact
was the major treatment. Now active wound dressing is
applied to prevent infection and accelerate the process of
healing. Thus therapeutic intervention is necessary to achieve
proper wound healing [176]. NO has excellent anti-bacterial
properties, which is of great importance to wound healing.
Moreover, NO is widely believed to be responsible for
promoting wound healing by re-epithelialization, improving
angiogenesis by stimulating growth factor expression and
increasing collagen synthesis [177,178]. Thus NO is essential
to wound healing.
Hydrogels can maintain a moist environment, as well as
allowing for oxygen permeability, elasticity and strength.
Given the advantages of hydrogels, combining hydrogel
technology with NO release ability has become a promising
strategy for wound dressing research. Masters et al. fabricated
a NO-releasing hydrogel wound dressing in 2002, aimed at
treating a diabetic mouse with impaired wound healing model
[179]. The hydrogel was prepared by ultraviolet light-initiated
polymerization from polyvinyl alcohol (PVA) with a NO
donor covalently coupled to the polymer backbone with NO
release of 0.5 mM and 5 mM. The in vivo data showed that the
time to complete closure was similar in control wounds and
NO-treated wounds. However, at 8th day control wounds were
signiﬁcantly smaller than NO-treated wounds. By days 10–13,
this delay was no longer apparent. Granulation tissue thickness
within the wounds at days 8 and 15 and scar tissue thickness
after wound closure were increased in animals exposed to
higher dose NO hydrogels. The mean scar tissue thickness at
29 days for control rats and NO-treated rats (5 mM) were 0.14
and 0.28 mm, respectively. As granulation tissue and scar
tissue are important for stable wounds, this study demonstrated
that NO-releasing hydrogels improve the quality of the wound
tissue.
Amadeu et al. prepared hydrogels using Pluronic F-127, a
well-known biologically inert block copolymer, with doped
GSNO, and then applied them daily to rat excisional wounds
for 4 d [180]. The re-epithelialized wound area was 77% larger
in the GSNO group than in the control group after 14 days.
Thin red-yellow collagen ﬁbers arranged perpendicular to the
surface were found in the granulation tissue of the control
group after 21 days, whereas in the GSNO-treated group
collagen ﬁbers were thicker and arranged parallel to the
surface. These results suggested that topical application of
GSNO-containing hydrogel during the early phase of rat
cutaneous wound repair accelerated wound closure and re-
epithelialization and inﬂuenced granulation tissue organization.
To further investigate the effects of NO in different phases of
healing, works by de Oliveira and coworkers were carried out.
The application of GSNO-containing hydrogel on excisional
wounds was set in the inﬂammatory (inf), proliferative (prol),and inﬂammatory and proliferative phases (infþprol) of rat
cutaneous wound repair [181]. Wound contraction of the
GSNO-(infþprol) group was faster than that of the control,
GSNO-(inf) and GSNO-(prol) groups by 5 d and 7 d after
wounding. Topical application of GSNO accelerated re-epithe-
lialization 14 d after wounding, mainly in the GSNO-
(infþprol) group. In addition, the GSNO-(infþprol) group
showed improved collagen ﬁber maturation and tissue organi-
zation, and a lower amount of inﬂammatory cells in the
superﬁcial and deep areas of the granulation tissue, compared
with the other groups. These results indicated that continual
NO availability for both inﬂammation and proliferation phases
was valuable for improved wound healing.
Using human subjects, de Oliveira and coworkers con-
structed hydrogels consisting of Synperonic F-127 and GSNO
or S-nitroso-N-acetylcysteine (SNAC) applied to the forearm
skin of eight subjects [182]. SNAC hydrogels produced a
1.2 fold greater maximum blood ﬂow compared to GSNO
hydrogels. The increase in blood ﬂow peaked at 30 min and
then remained elevated throughout the 3 h study. Topical
RSNOs produce a consistent, sustained and biologically
effective release of NO on human skin in vivo, which offers
advantages over currently available topical NO donors. Dermal
nitrite concentration-the oxidation product of NO-is directly
correlated with blood ﬂow at low and moderate blood ﬂow
levels. At high blood ﬂow levels there is a reduction in dermal
nitrite, which is ascribed to increased blood scavenging. To
further investigate the vasodilatory capacity and the possible
side-effects of topical application, GSNO incorporated Plur-
onicsF127 hydrogel was applied on the foot sole skin of
healthy and streptozotocin-induced diabetic rats [183]. The
hydrogel alone did not induce any changes in microvascular
ﬂow, while GSNO-containing hydrogel caused a twofold
increase in perfusion. This effect was similar in diabetic and
healthy animals. Topical GSNO application neither increased
the nitrotyrosine content of skin proteins, nor had any effect on
blood pressure or heart rate.
GSNO-containing F127 hydrogels have been improved to
obtain more slowly release NO. Recently, de Oliveira has
combined NO-releasing PVA-SNO ﬁlms that are capable of
releasing NO spontaneously with GSNO-containing F127
hydrogels [184]. Such combinations can attenuate the burst
NO release from the ﬁlm as well as enhance the total dose of
NO and prolong the release period. The PVA/SNO/F127 ﬁlm
indicated excellent performance in improving mouse wound
healing via acceleration of the inﬂammatory phase, enhancing
wound contraction and reducing the wound gap. The increase
in both collagen III expression and myoﬁbroblastic differentia-
tion further demonstrated the improvement. Thus combined
PVA-SNO/F127 promises a new method for promoting wound
healing.
Electrospun technology is also highly involved in develop-
ing wound dressing type materials. K.J. Balkus has bounded
NO to the acrylonitrile (AN)-based terpolymers backbone by
the formation of a diazeniumdiolate group [185]. In a 14 day
NO release study, the dressings released 79 μmol NO g1
polymer. The NO-loaded dressings were tested for NO release
Fig. 5. (A) Representative digital images of NO and control wounds at days 0, 7, and 14. Images are shown with equivalent scale. (B) Wound healing rates for
7 and 14 days post wounding. Wound area presented as percent of day 0. P values are noted. Adapted and reproduced from research originally published in Ref.
[185], copyright© Elsevier. (C) Photographs of wounds in animals treated with PBS, NapFF, Free NOþGAL, NO Gel and NO GelþGAL. (D) Percentage of
wound area left in different groups at Day 7 compared to the original wound area (mean7SEM) at Day 0. Signiﬁcance levels were set to: *po0.05, **po0.01,
and ***po0.001. Adapted and reproduced from research originally published in Ref. [187], copyright © RSC.
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with dressing application compared to empty dressings.
Studies were further carried out to evaluate wound healing
with dressing application performed weekly and daily. The
results suggested a markedly improved wound healing with
weekly NO application (Fig. 5A and B), and a more dramatic
improvement with daily application. The daily application of
NO bandages results in enhanced wound vascularity. These
data provided evidences for this novel NO-releasing dressing
as an effective wound healing strategy.
Deling Kong and his group have recently reported a stable
comb-shaped polymer (CS-NO) using glycosylated NO com-
pound as pendent chains and chitosan (CS) as backbone for
controlling NO release [186]. The on-demand release of NO
was achieved by regulating the decomposition process of the
CS-NO polymer. Because of its high stability, CS-NO poly-
mers can be processed into either a supportive membrane or an
injectable hydrogel, further demonstrating its clinical potential.In vivo administration of CS-NO solution signiﬁcantly
enhanced angiogenesis in diabetic mice with hind-limb ische-
mia. A protective effect of CS-NO against limb necrosis was
also observed. A molecular hydrogelator with enzyme-con-
trollable NO release property was also constructed, consisting
of a caged NO molecule and a naphthalene-capped short
peptide [187]. The introduction of different β-glycosidase
concentrations enabled the release of NO under control by
changing the sugar capping group situation. It is noteworthy
that this hydrogel not only promoted angiogenesis in the
wound bed, further accelerating the wound healing process
(Fig. 5C and D), but also cleared bioactive molecules and
minimized fast diffusion. Given local controllable delivery of
NO, this hydrogel system possesses huge potential applications
for tissue engineering and regenerative medicine.
As infection prevention is also beneﬁcial for wound healing,
NO-releasing hydrogel/glass nanocomposites have been evaluated
as typical wound healing agents for both control (non-infected)
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skin lesions in mice [188]. The results showed that the nanopar-
ticles exerted antimicrobial activity against MRSA and accelerated
infected wound closure, with minimal bacterial burden and greater
collagen content. Together, these data suggest that these NO-
releasing nanoparticles have the potential to serve as a novel class
of topically applied antimicrobials for the treatment of cutaneous
infections and wounds.
5. Nitric oxide as antimicrobial agent
Bacterial infection is a signiﬁcant clinical challenge and a
potentially crucial complication associated with implantedFig. 6. The numerous antibacterial mechanisms of nitric oxide and its byproducts (A
surfaces (B) compared to control surfaces (C). Adapted and reproduced from a re
Gram-negative E. coli (D) and after Gram-positive S. aureus (E) treatment with vario
and dead bacteria. Adapted and reproduced from research originally published in Rmedical devices including vascular catheters, pacemakers,
ventricular shunts and orthopedic implants [189]. Central
venous catheters of short-term implanted devices lead to
480,000 bloodstream infections every year with signiﬁcant
consequence [190,191]. For long-term orthopedic implants,
bacterial infection induced removal procedures are very
expensive, traumatic to the patient and potentially lethal. As
orthopedic devices ﬁnd increasing applications, the incidence
of infected implants also increases [192]. Infections associated
with medical implants, Lancet mellitus, cystic ﬁbrosis and non-
healing wounds are usually induced by bacterial bioﬁlms
[193–195]. The bioﬁlm is a community of microorganisms
attached to surface and surrounded by extracellular matrix,) lead to decreased bacterial viability and decreased adhesion on NO-releasing
view originally published in Ref. [15], copyright © RSC. Confocal images of
us materials. Merged images of Green (SYTO 9) and Red (PI) staining for live
ef. [215], copyright © Elsevier.
Table 1
NO-producing materials for in vivo applications. Note: Time points for NO release or ﬂux are the same as the in vivo time points unless otherwise speciﬁed. NO detection was conducted at 37 1C in PBS unless
otherwise speciﬁed. DACA-6/N2O2: NONOated N-(6-aminohexyl)-3-aminopropyl-trimethoxysilane, DBHD/N2O2: NONOated dibutylhexanediamine, DOSþKTpClPB: plasticized dioctyl sebacateþpotassium
tetrakis-4-chlorophenyl borate, ECC: extracorporal circulation, MAHMA/N2O2: (Z)-1-{N-Methyl-N-[6-(N-methylammoniohexyl)amino]}diazen-1-ium-1,2-diolate, PU: polyurethane, PVC: polyvinyl chloride, SR:
silicone rubber. I/M: Intima/media, the I/M ratio decrease is compared to injury alone unless otherwise speciﬁed. NOC-12/N2O2: NONOated N-ethyl-2-(1-ethyl-2-hydroxy-2-nitrosohydrazino)ethanamine, PDDC:
poly(1,12-dodecanediol-co-citrate), PEG: poly(ethylene glycol), PLGA: poly(lactic-co-glycolic acid), POC: poly(1,8-octanediol-co-citrate), PU: polyurethane. GSNO: S-nitrosoglutathione, PVA: poly(vinyl alcohol),
SNAC: S-nitroso-N-acetylcysteine, PPAam: plasma polymerized allylamine, PMMA: polymethyl methacrylate, Se: selenocystamine and SEDPA: 3,3-diselenodipropionic acid.





I/M ratio decrease Ref.
ECC MAHMA/N2O2 PVC Biamperometric Method Cumulative 20–25 μmol (1 d) Rabbit 4 h N/A [112]
ECC DBHD/N2O2 PVCþDOSþKTpClPB Chemiluminescence 15 1010 mol cm2 min1 Rabbit 4 h N/A [142]
ECC DBHD/N2O2 PVCþDOSþKTpClPB Chemiluminescence 2.33, 13.65, 20.64 and
39.10 1010 mol cm2 min1 (2, 10, 25 and
50 wt% donor, respectively)
Rabbit 4 h N/A [143]
ECC DACA-6/N2O2 SR Chemiluminescence
(23 1C, N2)
44 1010 mol cm2 min1 Rabbit 4 h N/A [147]
Arteriovenous grafts from
the common carotid artery
to the external jugular
vein
DBHD/N2O2 PVCþDOSþKTpClPB Chemiluminescence Peak ﬂux 60 1010 mol cm2 min1 and
110 1010 mol cm2 min1 for 4 and 8 wt%
donor, respectively (5 h)
Sheep 21 d N/A [148]
Coated stent deployed in
iliac arteries






NOC-12/N2O2 PLGA and PEG
(microspheres)









Diamine diol/N2O2 POC, PDDC Griess Peak ﬂux 35.4 109 mol cm2 min1 (4 h)
and 6.6 109 mol cm2 min1 (24 h),
respectively
Rat 14 d 38% [160]
Coated stent deployed in
femoral arteries
Se/NO Dopamine coating Griess 3.5 and 8 1010 mol cm2 min1 for SNAP
and GSNO, respectively
Dog 2 month N/A [164]
Coated stent deployed in
iliac arteries




the common carotid artery
to the external jugular
vein
DBHD/N2O2 PU Chemiluminescence 1.752 109 mol cm2 min1 (1 week);
3.3 1010 mol cm2 min1 (3 weeks)
Sheep 21 d N/A [166]
Rods implanted in carotid
and femoral arteries
DBHD/N2O2 PU Chemiluminescence Peak ﬂux 3.3 1010 mol cm2 min1 (12 h) Swine 8 h N/A [167]
Wound healing PVA/N2O2 PVA Griess (HEPES buffer pH
6, 20 1C)
Cumulative 0.055 μmol and 0.46 μmol for
0.5 mM and 5 mM NO hydrogels, respectively
(40 h)
Mice 29 d N/A [178]
Wound healing GSNO Pluronic F-127 N/A N/A Rat 14 d N/A [179,180]
Wound healing (blood
ﬂow)
GSNO and SNAC Synperonic F-127 Absorbance (545 nm, no
speciﬁed buffer)
50% decomposition of both donors Human 3 h N/A [181]
Wound healing (blood
ﬂow)
GSNO Pluronic F-127 N/A N/A Rat 30 min N/A [182]
Wound healing GSNO PVA/SNO/F-127 Chemiluminescence Peak ﬂux 125 (a.u.), then consistent for 50 min Mice 10 d N/A [183]
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response. As a result of impeded antibiotic therapy activity
and host defenses, bioﬁlms make implant removal or place-
ment the only possible option [196,197]. The complete
eradication of bioﬁlm bacteria calls for a substantially greater
antibiotic concentration than for planktonic bacteria because of
several speciﬁc defense mechanisms [198,199]. There is thus
an urgent need for developing materials that decrease protein/
bacterial adhesion and release highly effective and active
antimicrobial agents that can eradicate bioﬁlms.
As a reactive, diatomic free radical, high-output NO is
endogenously produced by mammalian immune induced by
activated macrophages, which leads to up-regulated iNOS
transcription in response to pathogens [200,201]. The interac-
tion of NO with reactive oxygen and nitrogen (superoxide
(O2), hydrogen peroxide (H2O2)) forms reactive antimicro-
bial derivatives including peroxynitrite (OONO), nitrogen
dioxide (NO2), dinitrogen trioxide (N2O3), dinitrogen tetroxide
(N2O4) and RSNOs. These derivatives have been reported to
interfere with DNA, resulting in deamination and oxidative
damage containing strand breaks, abasic sites and other DNA
alterations (Fig. 6A) [15,202]. On the other hand, the reactive
nitrogen intermediates can interact with reactive thiols, iron–
sulfur clusters, heme groups, amines, phenol or aromatic
amino acid residues of proteins [203]. The interacting sites of
NO2 and peroxynitrite with proteins are different. Thus NO
inhibits bacterial adhesion by destroying bacterial membrane
adhesion proteins and induces the dispersal of bacteria in
bioﬁlms. Early microbiological investigations have suggested
that NO gas can destroy plated colonies of bacteria [204].
Additionally, NO can inactivate metabolic enzymes by releas-
ing iron from metalloenzymes, thus inhibit critical metallopro-
teins in bacterial respiratory reactions [201]. Taking the in vivo
short half-life (on the order of seconds) of NO into considera-
tion, NO can function immediately around the implant and
avoid systemic toxicity concerns [205]. Thus special attention
has been paid to this NO-based strategy due to its broad
spectrum activity and localized action as an antibacterial agent.
As a typical representative, Mark Schoenﬁsch and his group
have long focused on developing NO-releasing materials that
reduce bacterial adhesion. Aminosilane-based sol–gels were
produced by mixing variable amounts of isobutyltrimethox-
ysilane (BTMOS) and (3-trimethoxysilylpropyl) diethylene-
triamine (DET3) [206]. Based on sol–gel chemistry, stable and
tunable NO-releasing materials were fabricated by exposing
sol–gels to high pressure NO gas at 5 atm for 72 h. Then
DET3-NONOate sol–gels could release NO up to 24 h
continuously. It was shown that NO, not the oxidation product
NO2
- , was responsible for reducing P. aeruginosa adhesion.
The experiments were carried out by immersing DET3 sol–gel
ﬁlms into P. aeruginosa PBS solutions containing 0.3 mM
NaNO2, but no signiﬁcant difference was found. The concen-
tration of NaNO2was set by the total concentration of readily
oxidized NO from NONOate-modiﬁed sol–gels during the
time of the experiments. The antimicrobial diversity of NO
was further explored by investigating other bacterial species
for orthopedic device coatings. Medical-grade stainless steel
Table 2
Concentration dependence of NO's cellular activity [16].
Nitric oxide concentration Signal transduction mechanism Physiological result
o1–30 nM Phosphorylation of extracellular signal-regulated kinases (ERK) Mediation of proliferative and protective effects
30–60 nM Phosphorylation of Akt (protein kinases B) Apoptosis protection
100 nM Stabilization of hypoxia-inducible factor 1α (HIF-1α) Tissue injury Protection
400 nM Phosphorylation and acetylation of p53 Cytostatic to apoptotic response, cell cycle arrest
41 μM Protein nitrosation (poly(ADP-ribose) polymerase, caspases) Apoptosis, full cell cycle arrest
Schema 2. The modiﬁcation of target substrate with NO-generating, NO-
releasing, NONOates layer and target molecules.
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of BTMOS and N-aminohexyl-N-aminopropyltrimethoxysi-
lane (AHAP3) [207]. NO release evaluation of the sol–gel-
coated SS was performed at both physiological and ambient
temperature. Sol–gel ﬁlms incubated at 25 1C presented a
lower NO ﬂux over the ﬁrst 24 h compared to at 37 1C, but
released period was more than ﬁve times longer. The bacterial
adhesion resistance of NO-releasing coatings was evaluated in
vitro by exposing to cell suspensions of Pseudomonas
aeruginosa, Staphylococcus aureus, and Staphylococcus epi-
dermidis at 25 1C and 37 1C. Cell adhesion to the bare SS and
to sol–gel-coated SS were similar, while adhesion on NO-
releasing surfaces was less for all investigated species and
temperatures. Although these results supported the applications
of NO as an antimicrobial agent for medical devices, the
inﬂuence of NO release on the surrounding tissue remained a
concern. The cytotoxicity of NO-releasing sol–gel derived
materials was investigated using L929 mouse ﬁbroblasts in
both direct and indirect contact models to differentiate between
the biological impact of the sol–gel matrix and NO release
[208]. The ﬁux of NO of AHAP3 (balance BTMOS) NON-
Oate-modiﬁed sol–gels reached 90 1010 mol cm2
min1. The introduction of PU as outer membrane signiﬁ-
cantly enhanced the stability of the sol–gel matrix without
signiﬁcantly suppressing the NO ﬁux. Direct contact studies
demonstrated a cytotoxic effect that was dependent on the
aminosilane content of the sol–gel. The use of a thin PUovercoat can eliminate this effect. Mild cytotoxicity depen-
dence of NO release for L929 ﬁbroblasts was discovered from
indirect contact studies. In vitro studies indicated that exposure
to NO ﬁuxes in excess of 30 1010 mol cm2 min1 for
24 h was cytotoxic. As the concentration of NO and associated
by-products released from the sol–gel after 24 h was quite
high, the in vivo response might be entirely different due to the
faster diffusion of NO and its by-products and biological
interaction of nitrogen oxide species [209]. Further in vivo
antibacterial activity of NO-releasing xerogel coatings was
investigated upon subcutaneous Staphylococcus aureus infec-
tion in a rat model [210]. The NO-releasing implants were
prepared by coating a medical-grade silicone elastomer with
AHAP3/BTMOS NONOate-modiﬁed sol–gels. Infection was
quantitatively and qualitatively evaluated after 8 d of implanta-
tion using microbiological and histological methods, respec-
tively. An 82% reduction in the number of infected implants
was achieved with the NO-releasing coating for high doses
(108 cfu ml1) of bacteria. Histology revealed that capsule
formation around infected bare silicone rubber controls was
immunoactive and that a bioﬁlm may have formed. Capsule
formation in response to NO-releasing implants had greater
vascularity in comparison with uninoculated or untreated
controls. These results suggest that NO-releasing coatings
can dramatically reduce the incidence of implant associated
infection. Nevertheless, the property of NO-releasing materials
to hinder bacterial adhesion in the presence of a promoting
protein layer has not yet been explored. AHAP3/BTMOS
NONOate-modiﬁed sol–gel coated PVC was described as
reducing ﬁbrinogen-mediated adhesion of S. aureus, S. epi-
dermidis, and Escherichia coli [211]. A negative correlation
was observed between NO surface ﬂux and bacterial adhesion.
For S. aureus and E. coli, the reduced adhesion correlated
directly with the NO ﬂux from 0 to 18 1010
mol cm2 min1. A similar dependence for S. epidermidis
was apparent from 10.8 to 18 1010 mol cm2 min1. At a
NO ﬂux of 18 1010 mol cm2 min1, surface coverage of
S. aureus, S. epidermidis, and E. coli was reduced by 96%,
48%, and 88%, respectively, compared to non-NO-releasing
controls. Thus NO-releasing sol–gel is an effective approach
for greatly reducing ﬁbrinogen-mediated adhesion of both
gram-positive and gram-negative bacteria in vitro.
Versatile NO-releasing coatings of RSNO-modiﬁed xerogels
have been described by Riccio [212]. Such RSNO-modiﬁed
xerogels are capable of generating NO for up to 2 weeks under
physiological conditions. Xerogels exhibit NO generation
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upon irradiation with light or exposure to copper, with NO
ﬂuxes proportional to wattage and concentration, respectively.
Note that xerogels displayed negligible fragmentation over a
2 week period. There was signiﬁcantly reduced P. aeruginosa
adhesion for RSNO-modiﬁed xerogels, conﬁrming the anti-
bacterial properties of these NO-releasing materials. It is worth
mentioning that ﬁbroblast cell viability on the xerogel surfaces
was maintained, further demonstrating the signiﬁcance of
RSNO modiﬁed xerogels as biomedical device coatings.
Further studies by Scott Nichols explored the NO ﬂux
necessary to suppress bacterial adhesion and decrease the
viability of different adhered bacteria (S. aureus, methicillin-
resistant S. aureus, S. epidermidis, E. faecalis, E. coli, and
P. aeruginosa) [213]. The xerogels were coated with PVC to
achieve consistent surface energy between NO-releasing and
control substrates. Fibrinogen was pre-adsorbed on these
materials so as to more accurately mimic conditions encoun-
tered in blood and promote bacteria adhesion. NO ﬂuxes
ranging from 12 to 30 1010 mol cm2 min1 universally
inhibited the bacterial adhesion by 480% for each strain
studied. Maximum bacteria killing activity (viability reduced
by 85–98%) was observed at the greatest NO payload
(1700 nmol cm2). These results illustrated the advantage of
active NO release as a strategy for inhibiting bacterial adhesion
in the presence of pre-adsorbed protein.
Except for sol–gels, chitosan derivatives have also been
widely used as NO-releasing scaffolds, since these materials
possess large amounts of amines that are necessary for the
formation of NONOates. It has been reported that the secondary
amine modiﬁed synthesized chitosan oligosaccharides signiﬁ-
cantly increase the NO payload, and the water-solubility allows
for beneﬁcial diffusion into P. aeruginosa bioﬁlms and associa-
tion with embedded bacteria [214]. Low molecular weight and
cationic chitosan oligosaccharides presented rapid association
with bacteria throughout the entire bioﬁlm, leading to enhance-
ment in bioﬁlm killing. At concentrations resulting in efﬁcient
killing of bacteria in P. aeruginosa bioﬁlms, the NO-releasing
and the control chitosan oligosaccharides elicited no signiﬁcant
cytotoxicity to mouse ﬁbroblast L929 cells in vitro. Thus the
potential of NO-releasing chitosan oligosaccharides as antimi-
crobial agents has been demonstrated. In addition, a polymer
composed of thermosensitive Pluronic F68 and branched
polyethylenimine (BPEI) housed NONOates also presented
antibacterial effect on Gram-negative E. coli, Gram-positive S.
aureus and MRSA (Fig. 6D and E) [215].
Materials capable of releasing NO have been extremely well
investigated for the goal of reducing bacterial adhesion and
implant-associated infections [15,123]. NO release from the
surface has been reported to affect bacterial adhesion and
bioﬁlm formation [216–218]. In addition, NO-dependent
antimicrobial activity has been shown in viruses, bacteria,
fungi, and parasites [201,219]. For further work, the NO
concentration (ﬂux) and NO-release kinetics should be opti-
mized to achieve maximum antibacterial adhesion and biocidal
activity, as well as minimal toxicity to mammalian cells.In vivo evaluation with bioﬁlm and infection models are also
required.6. Summary
Since the biological effects of NO were discovered about
three decades ago, over 590,000 publications have focused on
this topic. Numerous physiological processes associated with
NO and/or cGMP have been found, including relaxation of
smooth, cardiac and skeletal muscle, smooth muscle prolifera-
tion, endothelial permeability, platelet adhesion and aggrega-
tion, intestinal secretion and ion transport, calcium transport
and redistribution, hormone production and secretion, long-
term potentiation and memory, regulation of transcription,
neurotransmission, tissue injury and inﬂammation, pathogen
and tumor cytotoxicity [1]. This review has mainly focused on
the introduction of NO-based applications for biomedical
devices, strategies for anti-tumor, immune response, MSC
for myocardial infraction, and nano-scale research without
implant devices have not been reported here.
In this paper we have ﬁrst reviewed the identiﬁcation
process of NO and the physiological mechanisms of NO
synthesis. Both NO-releasing and NO-generating strategies
have been described, with NO-releasing strategies mainly
focusing on encapsulation of NO and LMW NO donors,
surface grafting donors and high pressurize NO to secondary
amine-functionalized agents. However, the clinical utility of
NO-releasing strategies is hindered by the limited NO payload,
and rapid and uncontrolled NO release. Long-term implanted
devices obviously require long-term and stable NO delivery,
and thus exhaustive NO release systems may not be ideal
candidates. Catalysts with high selectivity for reducing S-
nitrosothiol to produce NO were proposed for long-term
implanted devices. Such catalysts include thiol-containing
agents, organoselenium and transition metalions.
As summarized in Table 1, the worldwide expansion of NO
investigation has sped up progress in NO-producing materials
that are applied in vivo, including cardiovascular devices such
as extracorporeal circuits, vascular stents, bypass grafts, wound
healing and anti-microbial. Understanding the effects of
speciﬁc NO concentrations administrated to physiological loci
is also crucial (summarized in Table 2). Thus, these design
strategies and results are discussed and compared in release
kinetics, NO dose and biological effects. The excellent anti-
thrombosis, prevention in NIH, enhancement in EC prolifera-
tion, reduction in SMC proliferation and platelets activation/
aggregation are expected performances for cardiovascular
devices applications. Accelerated wound healing in each phase
and reduced bacterial adhesion and implant-associated infec-
tions also serve as a guide for the development of novel NO-
based therapeutics.
Improvements are still needed for NO-based strategies. One
such need is a method to efﬁciently store and controllably
deliver speciﬁc NO doses. Another is the need to establish
standard methods for reporting amount and duration of NO
Y. Yang et al. / Biosurface and Biotribology 1 (2015) 177–201196release to fully understand how speciﬁc NO release governs
biological responses. A third need is a combination of special
molecules with NO-producing materials to achieve multifunc-
tional goals for different applications (Schema 2). In this
review, NO-based strategies have proven their efﬁcacy to
extend release period, reduce cytotoxicity to normal cells and
tissues and display target functions in certain applications. In
the future, consistent reporting of NO-producing strategies
may facilitate rapid clinical translation of NO-based therapeu-
tics to positively impact the treatment of human diseases and
improve human life quality.
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